# Karyopharm Submits sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

> fda · REPORTED · 2026-08-01

Karyopharm Therapeutics filed a supplemental new drug application for selinexor combined with ruxolitinib for myelofibrosis under the FDA accelerated approval pathway in August 2026, targeting patients with an unmet need in this aggressive bone marrow disorder. The submission adds to selinexor's oncology portfolio even as data showed it failed to improve PFS in TP53 wild-type endometrial cancer.

About Karyopharm Therapeutics (selinexor): Karyopharm Therapeutics develops selinexor, a selective inhibitor of nuclear export (SINE) compound, for treating hematologic malignancies and solid tumors.

- Company: Karyopharm Therapeutics (selinexor)
- Sector: therapeutics
- Primary source: https://www.onclive.com/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.